StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note released on Saturday morning. The firm issued a hold rating on the stock.
Separately, HC Wainwright reduced their price objective on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating for the company in a research note on Monday, August 12th.
View Our Latest Analysis on Oncternal Therapeutics
Oncternal Therapeutics Price Performance
Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.03) by $0.14. The company had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.24 million. Oncternal Therapeutics had a negative net margin of 1,948.70% and a negative return on equity of 136.10%. During the same quarter in the previous year, the company earned ($3.00) EPS. Analysts expect that Oncternal Therapeutics will post -11.4 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 16.05% of the company’s stock.
About Oncternal Therapeutics
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
Further Reading
- Five stocks we like better than Oncternal Therapeutics
- Investing In Automotive Stocks
- 3 Small Cap Stocks That Insiders Are Buying
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.